HK1061868A1 - 對抗尼羅熱病毒的疫苗 - Google Patents

對抗尼羅熱病毒的疫苗

Info

Publication number
HK1061868A1
HK1061868A1 HK04104755.3A HK04104755A HK1061868A1 HK 1061868 A1 HK1061868 A1 HK 1061868A1 HK 04104755 A HK04104755 A HK 04104755A HK 1061868 A1 HK1061868 A1 HK 1061868A1
Authority
HK
Hong Kong
Prior art keywords
fever virus
vaccine against
nile fever
nile
vaccine
Prior art date
Application number
HK04104755.3A
Other languages
English (en)
Inventor
May Loosmore Sheena
Francis Audonnet Jean-Christophe
Maarten Minke Jules
Original Assignee
Merial Sas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merial Sas filed Critical Merial Sas
Publication of HK1061868A1 publication Critical patent/HK1061868A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
HK04104755.3A 2001-04-06 2004-07-02 對抗尼羅熱病毒的疫苗 HK1061868A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0104737A FR2823222B1 (fr) 2001-04-06 2001-04-06 Vaccin contre le virus de la fievre du nil
PCT/FR2002/001200 WO2002081621A2 (fr) 2001-04-06 2002-04-05 Vaccin contre le virus de la fievre du nil

Publications (1)

Publication Number Publication Date
HK1061868A1 true HK1061868A1 (zh) 2004-10-08

Family

ID=8862055

Family Applications (2)

Application Number Title Priority Date Filing Date
HK04104755.3A HK1061868A1 (zh) 2001-04-06 2004-07-02 對抗尼羅熱病毒的疫苗
HK16106775.0A HK1219412A1 (zh) 2001-04-06 2004-07-02 對抗尼羅熱病毒的疫苗

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16106775.0A HK1219412A1 (zh) 2001-04-06 2004-07-02 對抗尼羅熱病毒的疫苗

Country Status (22)

Country Link
EP (2) EP1377660B1 (zh)
JP (1) JP4426761B2 (zh)
AU (1) AU2002307971B2 (zh)
BE (1) BE2016C021I2 (zh)
BR (1) BRPI0208896B1 (zh)
CA (1) CA2448796C (zh)
CY (2) CY1117676T1 (zh)
DK (1) DK1377660T3 (zh)
ES (2) ES2566044T3 (zh)
FR (2) FR2823222B1 (zh)
HK (2) HK1061868A1 (zh)
HU (2) HU230122B1 (zh)
IL (3) IL158204A0 (zh)
LT (1) LTC1377660I2 (zh)
LU (1) LU93048I2 (zh)
MX (1) MXPA03008998A (zh)
NL (1) NL300806I2 (zh)
PL (2) PL210306B1 (zh)
RU (1) RU2283138C2 (zh)
SI (1) SI1377660T1 (zh)
WO (1) WO2002081621A2 (zh)
ZA (1) ZA200307620B (zh)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6977072B2 (en) 2000-10-27 2005-12-20 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
PL212212B1 (pl) * 2001-07-27 2012-08-31 Wyeth Corp Kompozycja szczepionki przeciwko zakażeniu wirusem Zachodniego Nilu, kompozycja końskiej szczepionki, szczepionka wirusa Zachodniego Nilu oraz zastosowania
AU2003296974A1 (en) * 2002-12-13 2004-07-14 Aventis Pasteur, Inc. Production of alvac on avian embryonic stem cells
EP1626708B1 (en) 2003-05-23 2017-11-29 Novartis Vaccines and Diagnostics, Inc. Immunogenic reagents from west nile virus
US7482017B2 (en) 2004-09-09 2009-01-27 Research Development Foundation Flavivirus variants having phenotypic variation and immunogenic compositions thereof
PL2251034T3 (pl) 2005-12-02 2018-07-31 Icahn School Of Medicine At Mount Sinai Chimeryczne wirusy prezentujące nienatywne białka powierzchniowe i zastosowania tych wirusów
SG193821A1 (en) 2008-08-29 2013-10-30 Boehringer Ingelheim Vetmed West nile virus vaccine
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
CA2756206A1 (en) 2009-03-27 2010-09-30 Academia Sinica Methods and compositions for immunization against virus
ES2679043T3 (es) * 2009-05-15 2018-08-21 Irx Therapeutics, Inc. Inmunoterapia de vacuna
TWI537385B (zh) 2010-11-04 2016-06-11 中央研究院 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法
RU2506093C1 (ru) * 2012-12-06 2014-02-10 Государственное научное учреждение Якутский научно-исследовательский институт сельского хозяйства Российской академии сельскохозяйственных наук Способ специфической профилактики ринопневмонии, сальмонеллезного аборта и мыта лошадей ассоциированной вакциной в условиях табунного содержания
BR112015021414B1 (pt) 2013-03-14 2020-11-10 Icahn School Of Medicine At Mount Sinai vírus da doença newcastle e seus usos
SG11201607130RA (en) 2014-02-27 2016-09-29 Viralytics Ltd Combination method for treatment of cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2909462A (en) 1955-12-08 1959-10-20 Bristol Myers Co Acrylic acid polymer laxative compositions
US5505941A (en) 1981-12-24 1996-04-09 Health Research, Inc. Recombinant avipox virus and method to induce an immune response
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US4745051A (en) 1983-05-27 1988-05-17 The Texas A&M University System Method for producing a recombinant baculovirus expression vector
EP0173552B1 (en) 1984-08-24 1991-10-09 The Upjohn Company Recombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
US4963481A (en) 1985-12-18 1990-10-16 Genetics Institute Inc Promoter system
DE3730599A1 (de) 1986-09-12 1988-07-07 Genentech Inc Verfahren zur kontinuierlichen herstellung von heterologen proteinen in eukaryontischen wirtszellen
DE3743138A1 (de) 1987-12-18 1989-09-14 Mayr Christian Gmbh & Co Kg Schleifringlose, elektromagnetische ueberlastkupplung
MY109299A (en) * 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5843456A (en) 1991-03-07 1998-12-01 Virogenetics Corporation Alvac poxvirus-rabies compositions and combination compositions and uses
EP0575491B1 (en) 1991-03-07 2003-08-13 Virogenetics Corporation Genetically engineered vaccine strain
US5382425A (en) 1992-01-13 1995-01-17 Syntro Corporation Recombinant swinepox virus
FR2702373B1 (fr) 1993-03-08 1996-06-07 Rhone Merieux Emulsions vaccinales fluides eau-dans-l'huile contenant une huile métabolisable.
EP0668355B1 (en) 1993-12-20 1999-04-07 Akzo Nobel N.V. Vaccine for the protection of horses against equine herpesvirus infection
FR2728794B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin recombinant aviaire a base de virus herpes aviaire, notamment contre la maladie de gumboro
FR2728795B1 (fr) 1994-12-30 1997-03-21 Rhone Merieux Vaccin vivant recombinant aviaire, utilisant comme vecteur un virus herpes aviaire
WO1996034109A1 (en) 1995-04-25 1996-10-31 Vical Incorporated Single-vial formulations of dna/lipid complexes
AU737243B2 (en) 1996-07-03 2001-08-16 Merial, Inc. Recombinant canine adenovirus (CAV) containing exogenous DNA
FR2751226B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies du cheval
FR2751225B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique aviaire
FR2751227B1 (fr) 1996-07-19 1998-11-27 Rhone Merieux Formule de vaccin polynucleotidique contre les pathologies canines, notamment les pathologies respiratoires et digestives
ATE292980T1 (de) 1996-10-11 2005-04-15 Univ California Immunostimulierende oligonucleotidekonjugate
DE69841690D1 (de) * 1997-02-28 2010-07-08 Acambis Inc Chimäre Impfstoffe gegen Flaviviren
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US6294176B1 (en) 1998-07-10 2001-09-25 Schering-Plough Veterinary Corp. Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
US6416763B1 (en) * 1998-08-28 2002-07-09 Hawaii Biotechnology Group, Inc. Recombinant nonstructural protein subunit vaccine against flaviviral infection
CA2375320C (en) 1999-06-10 2013-02-19 Merial Dna vaccines for pets or for animals used in sports
US6645740B1 (en) 1999-06-10 2003-11-11 Merial Limited Nucleic acids encodings equine GM-CSF
FR2796397B1 (fr) 1999-07-16 2006-09-01 Merial Sas Genes de calicivirus felin et vaccins notamment vaccins recombines

Also Published As

Publication number Publication date
RU2283138C2 (ru) 2006-09-10
NL300806I2 (zh) 2016-06-09
FR2823222B1 (fr) 2004-02-06
ES2566044T3 (es) 2016-04-08
PL207584B1 (pl) 2011-01-31
EP1377660A2 (fr) 2004-01-07
PL365210A1 (en) 2004-12-27
HUP0401868A3 (en) 2011-06-28
WO2002081621A3 (fr) 2003-02-20
JP4426761B2 (ja) 2010-03-03
FR16C0014I2 (fr) 2016-09-09
CY1117676T1 (el) 2016-12-14
RU2003132455A (ru) 2005-04-27
LTC1377660I2 (lt) 2017-04-25
EP1377660B1 (fr) 2016-01-13
HU230122B1 (hu) 2015-08-28
CA2448796A1 (en) 2002-10-17
BRPI0208896B1 (pt) 2016-06-07
LU93048I2 (fr) 2016-06-27
HUS1500047I1 (hu) 2017-03-28
FR16C0014I1 (zh) 2016-05-27
CA2448796C (en) 2012-11-20
MXPA03008998A (es) 2004-10-15
IL158204A (en) 2013-03-24
SI1377660T1 (sl) 2016-05-31
AU2002307971B2 (en) 2008-01-17
EP2979705A1 (fr) 2016-02-03
ES2767413T3 (es) 2020-06-17
FR2823222A1 (fr) 2002-10-11
DK1377660T3 (en) 2016-03-29
HK1219412A1 (zh) 2017-04-07
BE2016C021I2 (zh) 2021-03-23
BR0208896A (pt) 2004-07-20
ZA200307620B (en) 2005-07-27
PL210306B1 (pl) 2011-12-30
CY2016018I1 (el) 2016-12-14
IL185263A0 (en) 2008-01-06
JP2004531521A (ja) 2004-10-14
HUP0401868A2 (hu) 2004-12-28
CY2016018I2 (el) 2016-12-14
EP2979705B1 (fr) 2019-10-23
WO2002081621A2 (fr) 2002-10-17
IL158204A0 (en) 2004-05-12

Similar Documents

Publication Publication Date Title
HUS1500047I1 (hu) Rekombináns vakcina West Nile vírus ellen
MXPA03008961A (es) Composicion de vacuna.
FR14C0016I2 (fr) Vacccin west nile
GB0103170D0 (en) Vaccine composition
HUP0402259A3 (en) Vaccines
GB0407935D0 (en) Vaccine
DK1265633T3 (da) Vaccineadjuvans
HUP0303372A3 (en) Vaccine
EP1423141A4 (en) VACCINE
IL158428A0 (en) Vaccine composition comprising at least one hiv virus antigen
AU2002307971A1 (en) Vaccine against the nile fever virus
EP1395262A4 (en) NUCLEOSIDE-VACCINE-ADJUVANTS
EP1429615A4 (en) ORAL VACCINES
HUP0401182A3 (en) Vaccine composition comprising at least two valences, one enhanced with adjuvant and not the other
IS6184A (is) Bóluefni gegn ISA veiru
GB0105238D0 (en) Vaccines
GB0113552D0 (en) Vaccines
GB0124137D0 (en) Vaccine
GB0130823D0 (en) Vaccine
GB0128312D0 (en) Vaccine
GB0106589D0 (en) Vaccine
SI1436397T1 (sl) Cepivo proti virusu hepatitisa C
PL374051A1 (en) Salmonella vaccine
GB0100288D0 (en) Virus strains
GB0100430D0 (en) Virus strains

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: ADDITION OF INVENTOR: JULES MAARTEN MINKE

Effective date: 20170524

PE Patent expired

Effective date: 20220404